In fact, ERCC2 mutations could serve as a predictive biomarker for driving cisplatin responses that have been tested and validated in bladder cancers (Van Allen et al., 2014; Liu et al., 2016; Li et al., 2019). This evidence concerns the gene ERCC2 and urinary bladder carcinoma.